-
Product Insights
NewInsulin Receptor – Drugs In Development, 2024
The Insulin Receptor pipeline drugs market research report outlays comprehensive information on the Insulin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Oncology, Ophthalmology, and Central Nervous System which include indications of Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Graves' Ophthalmopathy, Retinopathy Of Prematurity, Alzheimer's Disease, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oleclumab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oleclumab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oleclumab in Solid Tumor Drug Details: Oleclumab (MEDI-9447) is under development...
-
Product Insights
NewFragile X Syndrome – Drugs In Development, 2024
Empower your strategies with our Fragile X Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1, and occurs both in males and females. Symptoms include delay in crawling, walking, or twisting; hyperactive or impulsive behavior; speech and language delay; and intellectual disability. The Fragile...
-
Product Insights
NewMajor Depressive Disorder – Drugs In Development, 2024
Empower your strategies with our Major Depressive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms....
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-036C in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-036C in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab Zovodotin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab Zovodotin in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zanidatamab Zovodotin in Solid Tumor Drug Details:Zanidatamab Zovodotin is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dorzagliatin in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dorzagliatin in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dorzagliatin in Type 2 Diabetes Drug Details: Dorzagliatin (Huatangning) is...
-
Company Insights
Innovation and Patenting activity of Hua Medicine Shanghai Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hua Medicine Shanghai Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...